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COST-MINIMIZATION ANALYSIS OF SEROLOGIC SCREENING
POLICY OPTIONS FOR US ARMY ACCESSION
IMMUNIZATIONS
Nevin RL1, Niebuhr DW1, Frick KD2
1Walter Reed Army Institute of Research, Silver Spring, MD, USA;
2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD,
USA
OBJECTIVES: To develop a cost-minimizing protocol to reduce
the administration of unnecessary immunizations through the
use of serologic screening to antibodies against selected diseases
for which enlisted accessions to the US Army currently receive
universal immunization. METHODS: A detailed decision tree
containing over 180,000 terminal nodes was constructed using
TreeAge software to model the variable costs of serologic screen-
ing and immunization series delivery among four policy options:
1) current policy, involving selective varicella serology based on
history; 2) universal hepatitis B serology with selective varicella
serology; 3) universal serology for hepatitis B, varicella, measles
and rubella; and 4) universal serology for hepatitis A and B, vari-
cella, measles and rubella. Parameters for the model included
levels of pre-existing immunity to each disease, rates of attrition
between vaccine doses, current vaccine and serologic screening
costs, and test sensitivity and speciﬁcity. Outcome measures
included total variable costs per accession, and probability of
missed immunization due to false positive test results. Due to 
the complexity of the tree, expected values were calculated via
10,000 runs of microsimulation repeated 1000 times to construct
conﬁdence intervals. RESULTS: All policy options with univer-
sal serologic screening demonstrated signiﬁcant variable cost
savings over current policy. Policy option three minimized costs,
with savings of $22.71 per accession (95% CI $22.68–$22.74).
Cost savings were qualitatively robust to probabilistic sensitiv-
ity analysis. Numbers of missed immunizations due to false pos-
itive test results were comparable between current and proposed
policies, with policy option three resulting in only 244 additional
missed immunizations per 100,000 accessions (95% CI 233–
256) relative to current policy. CONCLUSIONS: Due to high
levels of pre-existing immunity, enlisted accessions to the US
Army currently receive multiple unnecessary immunizations.
Universal serologic screening to hepatitis B, measles, rubella, and
varicella provides signiﬁcant variable cost savings without a clin-
ically signiﬁcant increase in disease susceptibility.
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ISPOR PHARMACOECONOMICS & OUTCOMES RESEARCH
ABSTRACTS: TRENDS & QUALITY INDICATORS
Smith MD1, McGhan WF2
1ISPOR, Lawrenceville, NJ, USA; 2University of the Sciences,
Philadelphia, PA, USA
OBJECTIVES: The purpose of this study was to perform a lon-
gitudinal content analysis to assess trends in pharmacoeconomic
and outcomes research abstracts presented at ISPOR Annual
Meetings and European Congresses as given in The ISPOR
Research Digest at www.ispor.org, as well as to assess abstract
quality indicators. METHODS: A database of 4605 abstracts
accepted for presentation at ISPOR meetings from 1998 through
2004 were analyzed for trends and quality indicators. Trends
were determined for topics and diseases. Quality indicators were
deﬁned as abstracts including “study perspective,” statistical
considerations (“conﬁdence interval”, “standard deviation”,
“±”, “mean/median”, “sensitivity analysis”), or “discounting”.
RESULTS: ISPOR had 14 Annual Meetings/Congresses during
1998–2004. The annual number of abstracts increased from 270
to 1013 with a seven-year total of 4605 with all topics and
disease categories increasing over time. The major topic areas
covered were cost evaluations (42%), clinical outcomes (7%),
quality-of-life/patient preferences (12%), methods and concepts
(17%) [43 % of which were on quality-of-life and 28% on cost
methods], and health policy (22%). The top four diseases (3959
disease-speciﬁed abstracts) were cardiovascular (17%), cancer
(9%), neurological/mental health (19%), and infectious diseases
(8%). With respect to quality indicators, a study perspective was
mentioned in 19% and discounting in 7% of the abstracts. For
statistical considerations, the percent of abstracts mentioning
mean/median (34%), sensitivity analysis (17%), standard devia-
tion (12%), and conﬁdence intervals (4%). The number of
abstracts with each of these quality indicators increased over the
study period. CONCLUSION: The number of abstracts has
increased over the study period for all topics and diseases.
Although the general abstract quality, as measured in this analy-
sis, was increasing, the percent of abstracts that include these
quality indicators needs improvement. Standards should be
adopted for the content of pharmacoeconomics and outcomes
research abstracts to provide more useful and meaningful 
information.
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BRIEF SUMMARY FORMATS OF DTCA TO IMPROVE
CONSUMER COMPREHENSION
Sansgiry SS, Kawatkar AA
University of Houston, Houston,TX, USA
OBJECTIVE: In January 2004, the Food and Drug Administra-
tion (FDA) proposed guidelines for the brief summary section of
prescription drug direct-to-consumer advertisements. In particu-
lar, they mentioned regarding the current consumer unfriendly
format which caused information overload and the overall sub-
optimal usefulness of the brief summaries and requested feed-
back to improve it. The objective of this study was to develop
and evaluate brief summary formats which would be favorable
for consumers and to provide practical implementation of FDA’s
suggestions. METHODS: A randomized within subjects study
was conducted to compare effectiveness of four (2 pre-existing
and 2 experimental) brief summary formats. All four formats
contained the same information appearing in the brief summary
for the prescription drug Pravachol®. A pre-validated reliable
survey instrument was administered to students enrolled in the
college of pharmacy in second year (N = 70) and third year (N
= 77), to test the effectiveness of formats developed on ease of
use, attitude towards formats, and satisfaction towards formats.
RESULTS: Multivariate analysis of variance test conducted on
the data (N = 147), indicated signiﬁcant positive effect of exper-
imental brief summary format on all measured variables (Wilk’s
lambda, p < 0.001). Individual analysis of variance tests on mean
scores for the four formats followed by post-hoc Scheffe test
revealed that currently existing formats had the lowest scores
with respect to ease of use, attitude towards formats and 
satisfaction with formats as compared to experimental formats
developed. CONCLUSION: The educational potential of the
brief summaries may not be served if consumers do not attempt
to read them due to their poor design and low readability
formats. The FDA should consider these ﬁndings and provide
clear guidelines to the industry to improve information and
format of brief summaries which may improve the expected out-
comes associated with these summaries as information sources
for consumers.
